Literature DB >> 7550127

Susceptibility of insulin to proteolysis in rat lung homogenate and its protection from proteolysis by various protease inhibitors.

Y Fukuda1, T Tsuji, T Fujita, A Yamamoto, S Muranishi.   

Abstract

The objective of this study was to determine the stability of insulin in rat lung homogenate and to confirm the effectiveness of various protease inhibitors for insulin delivery from the lung. The stability of insulin in rat lung homogenate was compared with that in the small intestine. Insulin was rapidly degraded in lung homogenate similarly to degradation in the small intestinal homogenate. The effects of various protease inhibitors on the degradation of insulin were studied in the lung. Protease inhibitors such as Na-glycocholate (Na-GC; 10 mM), aprotinin (10 mg/ml), soybean trypsin inhibitor (STI; 10 mg/ml) and bacitracin (20 mM) effectively reduced insulin degradation in lung homogenate. The rank order of effectiveness for decreasing the insulin hydrolysis in lung homogenate was bacitracin > aprotinin > STI > Na-GC. In addition, a slight correlation was observed between the in situ pulmonary absorption of insulin and its stability in vitro in the lung homogenate in the presence of various protease inhibitors. These findings suggest that the coadministration of protease inhibitors would be useful for improving the stability of insulin in the lung.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7550127     DOI: 10.1248/bpb.18.891

Source DB:  PubMed          Journal:  Biol Pharm Bull        ISSN: 0918-6158            Impact factor:   2.233


  9 in total

1.  Influence of absorption promoters on pulmonary insulin bioactivity.

Authors:  T Mahesh Kumar; Ambikanandan Misra
Journal:  AAPS PharmSciTech       Date:  2003       Impact factor: 3.246

Review 2.  Carrier-based strategies for targeting protein and peptide drugs to the lungs.

Authors:  Sally-Ann Cryan
Journal:  AAPS J       Date:  2005-03-24       Impact factor: 4.009

3.  Transport of drugs across the Xenopus pulmonary membrane and their absorption enhancement by various absorption enhancers.

Authors:  S Okumura; Y Fukuda; K Takahashi; T Fujita; A Yamamoto; S Muranishi
Journal:  Pharm Res       Date:  1996-08       Impact factor: 4.200

Review 4.  Pharmacology of bile acids and their derivatives: absorption promoters and therapeutic agents.

Authors:  M Mikov; J P Fawcett; K Kuhajda; S Kevresan
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2006 Jul-Sep       Impact factor: 2.441

5.  Enhancement of insulin transport across primary rat alveolar epithelial cell monolayers by endogenous cellular factor(s).

Authors:  Rana Bahhady; Kwang-Jin Kim; Zea Borok; Edward D Crandall; Wei-Chiang Shen
Journal:  Pharm Res       Date:  2007-04-19       Impact factor: 4.200

Review 6.  A Narrative Review of a Pulmonary Aerosolized Formulation or a Nasal Drop Using Sera Containing Neutralizing Antibodies Collected from COVID-19-Recovered Patients as a Probable Therapy for COVID-19.

Authors:  Nishat Fatima; Vichitra Kaushik; Amjad Ayoub
Journal:  Iran J Med Sci       Date:  2021-05

Review 7.  The lung as a route for systemic delivery of therapeutic proteins and peptides.

Authors:  R U Agu; M I Ugwoke; M Armand; R Kinget; N Verbeke
Journal:  Respir Res       Date:  2001-04-12

Review 8.  Bile Acids and Their Derivatives as Potential Modifiers of Drug Release and Pharmacokinetic Profiles.

Authors:  Nebojša Pavlović; Svetlana Goločorbin-Kon; Maja Ðanić; Bojan Stanimirov; Hani Al-Salami; Karmen Stankov; Momir Mikov
Journal:  Front Pharmacol       Date:  2018-11-08       Impact factor: 5.810

Review 9.  Key factors influencing ADME properties of therapeutic proteins: A need for ADME characterization in drug discovery and development.

Authors:  Jay Tibbitts; David Canter; Ryan Graff; Alison Smith; Leslie A Khawli
Journal:  MAbs       Date:  2015-12-04       Impact factor: 5.857

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.